Trials & R&D · first seen yesterday, updated yesterday
Lilly stopped showing its phase 1 pipeline. Is it playing R&D chess?
Lilly no longer publicly lists its earliest clinical programs. The move could buy the pharma giant time to test, kill and reposition drugs while competitors are still reading the board.
Summary from PharmaVoice.